326 related articles for article (PubMed ID: 14578681)
1. Positron emission tomography (PET): expanding the horizons of oncology drug development.
Hammond LA; Denis L; Salman U; Jerabek P; Thomas CR; Kuhn JG
Invest New Drugs; 2003 Aug; 21(3):309-40. PubMed ID: 14578681
[TBL] [Abstract][Full Text] [Related]
2. The role of positron emission tomography in pharmacokinetic analysis.
Fischman AJ; Alpert NM; Babich JW; Rubin RH
Drug Metab Rev; 1997 Nov; 29(4):923-56. PubMed ID: 9421680
[TBL] [Abstract][Full Text] [Related]
3. PET for in vivo pharmacokinetic and pharmacodynamic measurements.
Gupta N; Price PM; Aboagye EO
Eur J Cancer; 2002 Nov; 38(16):2094-107. PubMed ID: 12387835
[TBL] [Abstract][Full Text] [Related]
4. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
[TBL] [Abstract][Full Text] [Related]
5. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
6. What does positron emission tomography offer oncology?
Anderson H; Price P
Eur J Cancer; 2000 Oct; 36(16):2028-35. PubMed ID: 11044638
[TBL] [Abstract][Full Text] [Related]
7. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
Workman P; Aboagye EO; Chung YL; Griffiths JR; Hart R; Leach MO; Maxwell RJ; McSheehy PM; Price PM; Zweit J;
J Natl Cancer Inst; 2006 May; 98(9):580-98. PubMed ID: 16670384
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.
Fischman AJ; Alpert NM; Rubin RH
Clin Pharmacokinet; 2002; 41(8):581-602. PubMed ID: 12102642
[TBL] [Abstract][Full Text] [Related]
9. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.
Brady F; Luthra SK; Brown GD; Osman S; Aboagye E; Saleem A; Price PM
Curr Pharm Des; 2001 Dec; 7(18):1863-92. PubMed ID: 11772355
[TBL] [Abstract][Full Text] [Related]
10. Trends in nucleoside tracers for PET imaging of cell proliferation.
Toyohara J; Fujibayashi Y
Nucl Med Biol; 2003 Oct; 30(7):681-5. PubMed ID: 14499325
[No Abstract] [Full Text] [Related]
11. The use of imaging in preclinical drug development.
Vanderheyden JL
Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):374-81. PubMed ID: 19834446
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biologic Evaluation of a Novel
Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
[TBL] [Abstract][Full Text] [Related]
13. Fundamentals of positron emission tomography and applications in preclinical drug development.
Cherry SR
J Clin Pharmacol; 2001 May; 41(5):482-91. PubMed ID: 11361044
[TBL] [Abstract][Full Text] [Related]
14. Autoradiography with positron emitting isotopes in positron emission tomography tracer discovery.
Bergström M; Awad R; Estrada S; Mälman J; Lu L; Lendvai G; Bergström-Pettermann E; Långström B
Mol Imaging Biol; 2003; 5(6):390-6. PubMed ID: 14667493
[TBL] [Abstract][Full Text] [Related]
15. Realizing the full potential of PET for measuring the biodistribution of novel anticancer agents.
Jones T; Price P; Tavitian B
J Nucl Med; 2011 Sep; 52(9):1500. PubMed ID: 21824989
[No Abstract] [Full Text] [Related]
16. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
17. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.
Collingridge DR; Carroll VA; Glaser M; Aboagye EO; Osman S; Hutchinson OC; Barthel H; Luthra SK; Brady F; Bicknell R; Price P; Harris AL
Cancer Res; 2002 Oct; 62(20):5912-9. PubMed ID: 12384557
[TBL] [Abstract][Full Text] [Related]
18. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Clinical molecular imaging with positron emission tomography.
Saleem A; Charnley N; Price P
Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
